Associated Papers
Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study.
Soverini S et al.
Blood, 2020
Rapid Screen for Tyrosine Kinase Inhibitor Resistance Mutations and Substrate Specificity.
Taft JM et al.
Acs Chemical Biology, 2019
The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression in vitro.
Eadie LN et al.
Oncotarget, 2018
Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients.
Soverini S et al.
Oncotarget, 2016
26980736 (PubMed )
Supplement: oncotarget-07-21982-s001.pdf
Select a paper to view details